- Senseonics’ Eversence continuous glucose monitoring product provides the company with a tremendous opportunity, but developing this market doesn’t come cheap.
- In order to accelerate acceptance, Senseonics is investing in a new program, but in the short term this is adding to costs.
- In our view, the company will still have substantial cash needs next year, which keeps us on the sidelines here.
Senseonics Will Still Need To Go Back To The Markets
April 14th, 2019 · No Comments